Application of ESC 2021 colchicine in patients infected with COVID-19

Research Background

Research Background

ESC 2021The ECLA PHRI COLCOVID Trial

ESC 2021The ECLA PHRI COLCOVID Trial

Coronavirus disease 2019 is a severe acute respiratory syndrome caused by the infection of type 2 coronavirus (SARS-CoV-2).

Research design and results

Research design and results

ESC 2021The ECLA PHRI COLCOVID Trial

Inclusion criteria

● Adults (age ≥18 years old)

● Hospitalized patients suspected of being infected with COVID-19

● With severe acute respiratory syndrome: dyspnea, imaging manifestations of typical or atypical pneumonia, blood oxygen saturation ≤93%

Exclusion criteria

Exclusion criteria

● There are clear indications or contraindications for the use of colchicine

● The PCR test of SARS-CoV-2 was negative

● Creatinine clearance rate of chronic kidney disease <15 ml/min/m2

● Pregnant or breastfeeding women

Primary endpoint

Primary endpoint

1.

2.

Figure 1 Cohort study design

Figure 1 Cohort study design Figure 1 Cohort study design

(Figure 1) The study included 1279 COVID-19 hospitalized patients, of which 640 patients entered the colchicine group and 639 patients entered the control group

Table 1 Baseline characteristics of the two groups of patients

Table 1 Baseline characteristics of the two groups of patients Table 1 Baseline characteristics of the two groups of patients

(Figure 2) The incidence of the 28-day composite endpoint was 25.

Figure 2 The 28-day composite endpoint event hazard ratio

Figure 2 The 28-day composite endpoint event risk ratio Figure 2 The 28-day composite endpoint event risk ratio

(Table 2) In the colchicine group, the incidence of intubation needs or death caused by respiratory failure within 28 days was 143/640, while that of the control group was 173/639 (HR: 0.

Table 2 Efficacy Endpoints

Table 2 Efficacy Endpoint Table 2 Efficacy Endpoint

(Table 3) In terms of serious adverse events, the incidence of severe diarrhea was 11.

Table 3 Serious adverse events

Table 3 Serious Adverse Events Table 3 Serious Adverse Events

(Table 4) During the period from November 27, 2020 to March 4, 2021, 5,610 patients received colchicine treatment, and 5,730 patients received conventional treatment

Table 4 Mortality at 28-day follow-up

Table 4 Mortality after 28-day follow-up Table 4 Mortality after 28-day follow-up

(Table 5) The clinical trial registration started on March 23, 2020 and was completed on December 22, 2020

Table 5 The main clinical endpoints of the intentional analysis

Table 5 The main clinical endpoints of the intentional analysis Table 5 The main clinical endpoints of the intentional analysis

Analysis conclusion

Analysis conclusion

ESC 2021The ECLA PHRI COLCOVID Trial

ESC 2021The ECLA PHRI COLCOVID Trial

For hospitalized patients diagnosed with COVID-19, colchicine is beneficial for major respiratory events (respiratory death or ventilation), but colchicine does not significantly reduce the risk of death in hospitalized patients with COVID-19 on a statistical level And mechanical ventilation risks

Research discussion

Research discussion

ESC 2021The ECLA PHRI COLCOVID Trial

ESC 2021The ECLA PHRI COLCOVID Trial

Existing studies have shown that cytokine storm can cause severe clinical symptoms and even death in COVID-19 patients.

Expert Reviews

Expert Reviews

ESC 2021The ECLA PHRI COLCOVID Trial

ESC 2021The ECLA PHRI COLCOVID Trial

At present, the COVID-19 disease is still spreading globally

Leave a message here